Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company's supplemental new drug application for a lower dose QNASL (beclomethasone dipropionate) nasal aerosol, which is used for the treatment of seasonal and perennial allergic rhinitis in children ages 4 years to 11 years.
Sales of medical marijuana will remain within a burgeoning specialty channel without competition from traditional retail players like CVS Caremark, Rite Aid or Walgreens, Bloomberg Businessweek reported Tuesday.
After several months of sluggish retail sales, consumer shopping in the United States rebounded in April, according to the latest MasterCard SpendingPulse report, which aggregates national retail sales activity in the MasterCard payments network, coupled with estimates for all other payment forms, including cash and check.
Consumer year-over-year spending growth of 4.1% gained momentum in April 2014 compared with the prior month’s growth of 3.1%, driven by warmer weather, as well as the Easter shift into April this year, according to First Data SpendTrend analysis.
Unilever’s Simple Skincare range of facial products has kicked off the “Kind to City Skin” — a global initiative designed to help women understand the impact that city living — both environmental and lifestyle-related factors — can have on their faces.
Bayer HealthCare on Monday announced that the Food and Drug Administration approved the company's new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.
Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro. The drug is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants.
The Consumer Healthcare Products Association on Friday filed comments to the Food and Drug Administration in response to the agency’s Notice of Public Hearing and Request for Comments on the Over-the-Counter Drug Monograph System, also referred to as the OTC Drug Review.